Clinical Research Details
Title:
Phase I/II Study Utilizing High Dose Busulfan and Melphalan Followed by Escalating Bortezomib as Conditioning in Autologous Peripheral Blood Stem Cell Transplantation for Participants With Multiple Myeloma
Purpose:
The purpose is to evaluate efficacy as measured by response rate through a phase I/II non-randomized trial that utilizes a preparative regimen consisting of intravenous busulfan plus melphalan, both at standard dosages, followed by escalating doses of bortezomib, supported by transplantation of autologous hematopoietic stem cells.
Study Number:
201610
Number of Patients:
36
Elgibility:
To be eligible, participants must be diagnosed with multiple myeloma and must have:
• Underwent successful pre-transplant work up
• ECOG Performance Status = 2
Treatment:
Participants will receive four doses of busulfan, one dose of melphalan, followed by one dose of bortezomib as a preparative regimen for autologous stem cell transplantation.
Principal Investigator:
Enrollment Phone:
(708) 327-3157